---
layout: post
title: "Endogenous Cushing's Syndrome: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:56:45 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-19419
original_published: 2023-09-08 00:00:00 +0000
significance: 8.00
---

# Endogenous Cushing's Syndrome: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 08, 2023 00:00 UTC
**Document Number:** 2023-19419

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Endogenous Cushing's Syndrome: Developing Drugs for Treatment." The purpose of this guidance is to provide recommendations to sponsors regarding clinical trial designs for drugs intended for the treatment of adults with endogenous Cushing's syndrome for whom surgery is not an option or has not been curative. This draft guidance is intended to focus continued discussions among FDA's Division of General Endocrinology, pharmaceutical sponsors, the academic community, and the public.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/08/2023-19419/endogenous-cushings-syndrome-developing-drugs-for-treatment-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2023-19419

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
